LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivaNova PLC on February 5, 2024, reporting events occurring on February 1, 2024. The filing primarily addresses significant changes in executive leadership and board composition.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Vladimir A. Makatsaria was appointed as Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024.
- Leadership Transition: William A. Kozy will step down as Interim CEO on March 1, 2024, but will remain as Chair of the Board.
- Compensation Package: Mr. Makatsaria's employment agreement includes:
- Annualized base salary of $930,000.
- Target annual bonus of 110% of base salary (pro-rated for 2024).
- Long-term equity incentive awards with a target grant-date value of $5,350,000.
- Special inducement equity grants totaling $1,500,000, vesting over four years.
- Sign-on cash bonus of $200,000.
- Relocation benefits from New York City to Houston, Texas.
Outlook, Risks, and Management Commentary
The filing includes no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the announcement of the leadership change and the background of the new CEO, who previously served as Company Group Chairman at Johnson & Johnson MedTech.
Key Facts for Investor Verification
- Confirm the effective date of the CEO transition (March 1, 2024).
- Verify the total value of the compensation package, including the $5,350,000 in long-term equity and $1,500,000 in inducement grants.
- Review the terms of the severance benefits outlined in the employment agreement for involuntary termination.
- Monitor the strategic direction under the new CEO, given his background in surgical technologies at Johnson & Johnson.